- Home
- BNKK vs BIVI Comparison
BNKK vs BIVI Comparison
Compare BNKK & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BNKK | BIVI |
|---|---|---|
| Founded | 2018 | 2013 |
| Country | United States | United States |
| Employees | 8 | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.3M | 11.5M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | BNKK | BIVI |
|---|---|---|
| Price | $1.64 | $1.45 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 320.6K | 86.3K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.11 | $0.88 |
| 52 Week High | $7.19 | $9.09 |
Technical Indicators
Market Signals| Indicator | BNKK | BIVI |
|---|---|---|
| Relative Strength Index (RSI) | 26.73 | 50.91 |
| Support Level | $0.12 | $1.42 |
| Resistance Level | $2.90 | $1.52 |
| Average True Range (ATR) | 0.25 | 0.11 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 0.00 | 44.41 |
Price Performance
Historical ComparisonAbout BNKK Bonk Inc.
Bonk Inc is a publicly traded company focused on building a digital asset treasury centered around the BONK ecosystem on the Solana blockchain. It generates revenue through a recurring interest in the memecoin launchpad letsBONK.fun and actively manages its treasury of BONK tokens.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.